Review Article

Coronavirus Disease 2019-Related Multisystem Inflammatory Syndrome in Children: A Systematic Review and Meta-Analysis

Ji-Gan Wang,1 Zhi-Juan Zhong,2 Meng Li,1 Jun Fu,1 Yu-Heng Su,1 You-Min Ping,1 Zi-Ji Xu,1 Hao Li,1 Yan-Hao Chen,1 and Yu-Li Huang1

1Pediatrics Department, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
2Pediatrics Department, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, China

Correspondence should be addressed to Ji-Gan Wang; 354713144@qq.com

Received 2 February 2021; Revised 17 May 2021; Accepted 10 July 2021; Published 23 July 2021

Academic Editor: Danni Zheng

Copyright © 2021 Ji-Gan Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. This study aimed to describe the clinical symptoms, laboratory findings, treatment, and outcomes of coronavirus disease 2019-related multisystem inflammatory syndrome in children to provide a reference for clinical practice. Methods. We employed a literature search of databases such as PubMed, Web of Science, EMBASE, and Johns Hopkins University for articles on COVID-19-related multisystem inflammatory syndrome in children published between April 1, 2020, and January 15, 2021. High-quality articles were selected for analysis on the basis of their quality standard scores. Using R3.6.3 software, meta-analyses of random- or fixed-effects models were used to determine the prevalence of comorbidities. Subgroup analysis was also performed to determine heterogeneity. Results. A total of 57 articles (2,290 pediatric patients) were included in the study. Clinical Manifestations. Incidences of fever, gastrointestinal symptoms, respiratory symptoms, and musculoskeletal symptoms (myalgias or arthralgias) were 99.91% (95% CI: 99.67–100%), 82.72% (95% CI: 78.19–86.81%), 53.02% (45.28–60.68%), and 14.16% (95% CI: 8.4–21.12%), respectively. The incidences of rash, conjunctival injection, lymphadenopathy, dry cracked lips, neurologic symptoms (headache, altered mental status, or confusion), swollen hands and feet, typical Kawasaki disease, and atypical Kawasaki disease were 59.34% (95% CI: 54.73–63.87%), 55.23% (95% CI: 50.22–60.19%), 27.07% (95% CI: 19.87–34.93%), 46.37% (95% CI: 39.97–52.83%), 28.87% (95% CI: 22.76–35.40%), 28.75% (95% CI: 21.46–36.64%), 17.32% (95% CI: 15.44–19.29%), and 36.19% (95% CI: 21.90–51.86%), respectively. The incidences of coronary artery dilation, aneurysm, pericardial effusion, myocarditis, myocardial dysfunction, high troponin, and N-terminal pro-B-type natriuretic peptide were 17.83%, 6.85%, 20.97%, 35.97%, 56.32%, 76.34%, and 86.65%, respectively. The incidences of reduced lymphocytes, thrombocytopenia, hypoalbuminemia, elevated C-reactive protein, ferritin, LDH, interleukin-6, PCT, and FIB were 61.51%, 26.42%, 77.92%, 98.5%, 86.79%, 80.59%, 89.30%, 85.10%, and 87.01%, respectively. PICU Hospitalization Rate and Mortality. The incidences of PICU hospitalization or with shock were 72.79% and 55.68%, respectively. The mortality rate was 1.00%. Conclusion and Relevance. PICU hospitalization and shock rates of multisystem inflammatory syndrome in children associated with COVID-19 were high, and its cumulative multiorgans and inflammatory indicators are increased, but if treated in time, the mortality rate was low.

1. Introduction

The transmission of coronavirus disease 2019 (COVID-19) was recognized by the World Health Organization as a global pandemic in March 2020 [1]. In the early stages of the pandemic, it was widely believed that children were not susceptible to infection and the disease was benign disease [2]. However, as the pandemic progressed and children died, people began to pay attention to this part of the population [3]. In April 2020, eight children were reported in the United Kingdom with hyperinflammatory shock, showing features similar to atypical Kawasaki disease—Kawasaki disease shock syndrome [4]. This first report was followed by more in the United States and other regions thereafter [5] and became known as “multisystem inflammatory syndrome in children” (MIS-C). The syndrome was clinically similar to Kawasaki disease (KD), as well as toxic shock syndrome and secondary lymphoid tissue cells hyperplasia/macrophage...
activation syndrome [6]. Since little was known about this new syndrome, people were extremely worried due to the severity of the condition. Therefore, a systematic description of the clinical manifestations, laboratory tests, and prognosis of this disease is necessary.

2. Materials and Methods

2.1. Study Registration. The study is reported in accordance with the 2009 guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Supplementary Materials) [7]. This systematic review and meta-analysis is registered in the Prospero International Prospective Register of Systematic Reviews (CRD42020208680).

2.2. Definition Criteria. As the disease was discovered in April as a new disease, the name and definition of the disease during the first 2 months were quite different. Therefore, “pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 pandemic (PIMS-TS)” and “multisystem inflammatory syndrome in children (MIS-C)” and “SARS-CoV-2-induced Kawasaki-like hyper-inflammatory syndrome (SCiKH syndrome)” were included in the analysis [8].

2.3. Computer Retrieval of Articles. Searches for publications reporting on MIS-C associated with COVID-19 in PubMed, Web of Science, Embase, and Johns Hopkins University published data were conducted. The retrieval time for data was from April 1, 2020, to January 15, 2021. At the same time, online database and manual retrievals were conducted, and the references included in the articles were also traced. Subjects and free words were used in the retrieval, and adjustments were made according to the characteristics of different databases. Data retrieval was not limited to any language or country. For the PubMed search strategy, three search categories were used in combination (#1 AND #2 AND #3) as follows:

- #1 (children) OR (child)) OR (kid) OR (pediatric) OR (paediatric)
- #2 (multisystem inflammatory syndrome) OR (MIS-C) OR (PIMS-TS) OR (SCiKH syndrome) OR (SARS-CoV-2–induced Kawasaki-like hyper-inflammatory syndrome) OR (Kawasaki)
- #3 (2019-nCoV) OR (COVID-19) OR (SARS-CoV-2) OR (Corona Virus Disease 2019) OR (coronavirus)

2.4. Literature Screening and Data Extraction. Two researchers (J. G. W. and Z. J. Z.) independently searched and screened articles as well as collected and cross-checked data. If there was any dispute, it was discussed or negotiated with a third researcher (M. L.).

Inclusion criteria were (1) study type: cohort studies, case-control studies, case series, and cross-sectional studies; (2) participants: (<21 years old) with MIS-C; and (3) observation index: clinical manifestations (including fever and cough), laboratory examination, severe cases, and deaths.

Exclusion criteria were (1) adult cases; (2) case reports; and (3) incomplete, missing, or inaccessible data.

The level of laboratory test items was determined according to the following standards (reference ranges were obtained from Nelson Textbook of Pediatrics): normal white blood cell: 5.5 to 12.0 × 10^9/L, leukocytosis: more than 12.0 × 10^9/L, leukopenia: less than 5.5 × 10^9/L, lymphopenia: less than 1.2 × 10^9/L, high PCT: more than 0.046 ng/mL, high CRP: more than 10 mg/L, high LDH: more than 300 U/L, high ALT: more than 45 U/L, high AST: more than 50 U/L, high creatinine: more than 0.55 mg/L, high ferritin: more than 150 ng/mL, high interleukin-6: more than 5 pg/mL, and high N-terminal pro-B-type natriuretic peptide: more than 194.0 pg/mL. We excluded studies that did not report original data or clear diagnostic criteria and no relevant outcome.

Diagnostic criteria of coronary artery dilatation (CAD) and coronary artery aneurysms (CAA) were as follows: Z value < 2 is no CAD, 2 ≤ Z value < 2.5 is CAD, 2.5 ≤ Z value < 5 is small CAA, CAA inner diameter < 0.8 cm and 5 ≤ Z value < 10 is medium CAA, and CAA inner diameter ≥ 0.8 cm and Z value ≥ 10 is large or huge CAA.

2.5. Quality Evaluation of the Included Studies. This was a case series study that adhered to the National Institute for Clinical excellence guidelines for quality evaluation [9]. The evaluation items were as follows: (1) cases in the case series came from medical institutions at different levels and from different research centers; (2) the research hypothesis or purpose was clearly described; (3) clear reports were included in the exclusion criteria; (4) measurement results were clearly defined; (5) collected data achieved the expected purpose; (6) the patient recruitment period was clearly defined; (7) the main findings were clearly described; (8) the results were analyzed and reported in layers. One point was awarded for each item (maximum 8 points), with a total score ≥ 4 indicating high-quality research. Two researchers independently evaluated the quality and cross-checked the results.

2.6. Statistical Analysis. Statistical analyses were conducted using the Meta 4.11-0 Package in R Software Version 3.6.3. Before meta-analysis, the conversion of the original rate to conform to a normal distribution was carried out first. The conversion methods included PRAW (original rate without conversion), PLN (logarithmic conversion), PLOGIT (logit conversion), PAS (arc sine conversion), and PFT (Free–Tukey dual arc sine conversion). The meta-analysis was carried out on the normal distribution or mode closest to the state distribution. A random- or fixed-effects model model was selected according to heterogeneity: if P < 0.1 and I^2 ≤ 50%, a fixed model was used; and if P < 0.1 and I^2 > 50%, the study was considered to have heterogeneity and a random-effects
model was used [10]. According to the sample size of each independent study, different weights were given and the effect rate of each independent sample was combined to calculate the incidence rate and 95% confidence interval (CI). To explore heterogeneity, we performed subgroup analyses based on the location (region) and sample size (<50, ≥50). Finally, a funnel graph was created and the publication offset was statistically tested using the Egger method.

2.7. Ethics. As this is a systematic review, ethical approval was not required.

3. Results

3.1. Literature Screening Process and Results. A total of 685 related articles were initially retrieved, of these, 331 duplicate articles were deleted and an additional 227 articles were deleted based on a review of the titles and abstract. Finally, after layer-by-layer screening, a total of 57 articles [5,11–66] were included (2,290 children), the majority of which were from Europe and the United States. The male to female ratio was 1.49:1. The literature screening process and results are shown in Figure 1. The characteristics of the included studies are shown in Supplementary Table 1.

3.2. Basic Characteristics and Quality Evaluation Results of the Included Studies. The quality characteristics of all included studies were 4–8 points, indicating high-quality studies (≥4 points; Supplementary Table 2).

3.3. Meta-Analysis Results (Table 1)

3.3.1. Clinical Manifestations. The incidences of fever, gastrointestinal symptoms, and musculoskeletal symptoms (myalgias or arthralgias) were 99.91% (95% CI: 99.67–100%), 82.72% (95% CI: 78.19–86.81%), and 14.16% (95% CI: 8.4–21.12%), respectively.

The incidences of rash, conjunctival injection, lymphadenopathy, dry cracked lips, neurologic symptoms (headache, altered mental status, or confusion), swollen hands and feet, typical KD, and atypical KD were 59.34% (95% CI: 54.73–63.87%), 55.23% (95% CI: 50.22–60.19%), 27.07% (95% CI: 19.87–34.93%), 46.37% (95% CI: 39.97–52.83%), 28.87% (95% CI: 22.76–35.40%), 28.75% (95% CI: 21.46–36.64%), 17.32% (95% CI: 15.44–19.29%), and 36.19% (21.90–51.86%), respectively.

3.3.2. Cardiac Damage. The incidences of coronary artery dilation, aneurysm, pericardial effusion, myocarditis, cardiac systolic function affects, high troponin, and N-terminal pro-B-type natriuretic peptide were 18.2% (95% CI: 12.0–25.5%), 6.7% (95% CI: 2.8–12.1%), 21.5% (95% CI:14.3–29.7%), 36% (95% CI: 32.9–39.1%), 62.5% (95% CI: 51.2–73.3%), 79.6% (95% CI: 66.7–90.0%), and 89.7% (95% CI: 79.1–96.7%), respectively.

3.3.3. Laboratory Examinations. The incidences of reduced lymphocytes, thrombocytopenia, hypoalbuminemia, elevated white blood cell count, leukopenia, C-reactive protein (CRP), ferritin, LDH, erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6), PCT, and FIB were 61.51% (95% CI: 50.73–71.74%), 26.42% (95% CI: 18.19–35.58%), 77.92% (95% CI: 66.00–87.85%), 55.30% (95% CI: 40.47–69.66%), 4.40% (95% CI: 0.14–14.13%), 98.5% (95% CI: 95.04–99.65%), 90% (95% CI: 80.9–97.0%), 80.59% (95% CI: 42.53–99.73%), 82.44% (95% CI: 73.47–89.89%), 89.3% (95% CI: 75.3–97.88%), 85.10% (95% CI: 75.65–92.55%), and 87.01% (95% CI: 73.97–95.98%), respectively.

3.3.4. Organ Injury. The incidences of liver function damage, kidney damage, and lung ground-glass changes were 46.29% (95% CI: 32.78–60.08%), 27.67% (95% CI: 20.83–35.08%), and 24.69% (95% CI: 19.74–29.99%), respectively.

3.3.5. PICU Hospitalization Rate and Mortality. The incidences of PICU hospitalization or with shock were 72.79% (95% CI: 66.75–78.44%) and 55.68% (95% CI: 48.50–62.74%), respectively. The mortality rate was 1.00% (95% CI: 0.61–1.48%).

3.3.6. Treatment. The proportions of cases using invasive mechanical ventilation, ECMO, IVIG, aspirin, glucocorticoid, vasoactive agent, positive inotropic, IL-1 receptor antagonist, IL-6 receptor antagonist, or infliximab antibiotic were 22.68% (95% CI: 16.91–29.02%), 0.48% (95% CI: 0.03–1.42%), 82.15% (95% CI: 76.53–87.14%), 67.97% (95% CI: 53.77–80.64%), 59.32% (95% CI: 52.02–66.43%), 45.79% (95% CI: 42.62–48.97%), 58.99% (95% CI: 48.57–69.02%), 3.61% (95% CI: 0.68–8.73%), 10.9% (95% CI: 2.79–23.42%), 6.68% (95% CI: 3.03–11.62%), and 90.96% (95% CI: 82.29–96.92%), respectively.

3.4. Subgroup Analysis

3.4.1. Heterogeneity. In this study, except for fever, other factors had obvious heterogeneity (I², 39–98). In order to explore the source of heterogeneity, the subjects were classified according to region (United States, Europe, and other countries) and sample size (<50, ≥50) and grouped by gastrointestinal symptoms, lymphopenia, and respiratory symptoms. The results of subgroup analyses were consistent with the overall results, and there was no significant difference between the heterogeneity of each subgroup and overall heterogeneity, indicating that the region and sample size of the study were not the main source of heterogeneity (Table 2).

3.4.2. Sensitivity Analysis. Sensitivity analysis was conducted for gastrointestinal symptom indicators. After removing each study in turn, the statistics were combined...
again. The results did not change significantly, indicating that the results were relatively stable (Figure 2).

3.5. Publication Bias. According to the meta-analysis of gastrointestinal symptoms, a funnel plot was drawn. The results showed that there was good symmetry between the left and right distributions of each research point (Figure 3). The Egger test ($P = 0.943$) results suggested that there are no publication biases.

4. Discussion

It seems that the nomenclature for multisystem inflammatory syndrome in children has not been unified, with some countries referring to it as "pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 pandemic (PIMS-TS)" or "SARS-CoV-2-induced KD-like hyperinflammatory syndrome (SciKH syndrome)"; however, "multisystem inflammatory syndrome in children (MIS-C)" is the most commonly used term [67]. Although the definition of this disease is still inconsistent, its common characteristics include fever, multiple organ damage, and increased inflammatory indicators. Since April 2020, eight cases of children with high inflammatory shock COVID-19 were reported in London, UK [5], which increased attention on the recently recognized syndrome due to its severe effects, disbanding the previous notion that children with COVID-19 presented with a mild disease course. Almost 100% of these patients had fever, and only one study from Iran [24] reported patients that did not have fever (4/45 patients). In addition to fever, gastrointestinal symptoms (82.72%) are the second most common clinical manifestation. Because children are often accompanied by cardiac inflammation and some common features of KD, the term COVID-19-related MIS-C was created to describe this novel manifestation and establish diagnostic criteria. The clinical manifestations included repeated high fever, rash, conjunctivitis, peripheral edema, and extensive limb pain, accompanied by obvious gastrointestinal symptoms, which made it difficult to perform volume resuscitation. Finally, norepinephrine and milrinone were needed to provide hemodynamic

Figure 1: Flow diagram for identification of selected studies in the meta-analysis.
Table 1: Meta-analysis results.

| Outcome indicators          | Number of included studies | Sample size | $P$ values | Heterogeneity | Effect of model | Meta-analysis results |
|-----------------------------|----------------------------|-------------|------------|---------------|------------------|----------------------|
|                             |                            |             | $I^2$      | $t^2$         |                  | R% (95% CI)         |
| **Clinical features**       |                            |             |            |               |                  |                     |
| Fever                       | 47                         | 1367        | 0.86       | 0             | 0.71             | Fixed               | 99.94% (99.74%-100%) |
| Rash                        | 46                         | 1953        | <0.01      | 64.30%        | 0.0118           | Random              | 59.34% (54.73%-63.87%) |
| Dry cracked lips            | 30                         | 1634        | <0.01      | 77.10%        | 0.0181           | Random              | 46.37% (39.97%-52.83%) |
| Conjunctival injection      | 37                         | 1799        | <0.01      | 65.70%        | 0.0112           | Random              | 55.23% (50.22%-60.19%) |
| Swollen hands and feet      | 24                         | 998         | <0.01      | 81.30%        | 0.0291           | Random              | 28.75% (21.46%-36.64%) |
| Lymphadenopathy             | 21                         | 1513        | <0.01      | 86.60%        | 0.0267           | Random              | 27.07% (19.87%-34.93%) |
| Gastrointestinal symptoms   | 51                         | 2126        | <0.01      | 80.00%        | 0.0264           | Random              | 82.72% (78.19%-86.81%) |
| Neurological symptoms       | 31                         | 1668        | <0.01      | 82.10%        | 0.0248           | Random              | 28.87% (22.76%-35.40%) |
| Respiratory symptoms        | 36                         | 1753        | <0.01      | 86.85%        | 0.0378           | Random              | 53.02% (45.28%-60.68%) |
| Arthralgias                 | 9                          | 393         | 0.03       | 53.50%        | 0.0084           | Random              | 14.16% (8.4%-21.12%)  |
| Typical Kawasaki disease    | 32                         | 1481        | <0.01      | 92.60%        | 0.0798           | Random              | 17.32% (15.44%-19.29%) |
| Atypical Kawasaki disease   | 18                         | 559         | <0.01      | 91.60%        | 0.0981           | Random              | 36.19% (21.90%-51.86%) |
| **Cardiac damage**          |                            |             |            |               |                  |                     |
| Coronary artery dilation    | 35                         | 927         | <0.01      | 64.20%        | 0.0186           | Random              | 17.83% (13.29%-22.87%) |
| Aneurysm                    | 26                         | 734         | <0.01      | 66.40%        | 0.0188           | Random              | 6.85% (3.68%-10.92%)  |
| Pericardial effusion        | 24                         | 1244        | <0.01      | 69.30%        | 0.0137           | Random              | 20.97% (15.69%-26.79%) |
| Myocarditis                 | 20                         | 930         | <0.01      | 92.10%        | 0.098            | Random              | 35.97% (32.92%-39.08) |
| Heart systolic function     | 35                         | 1308        | <0.01      | 85.70%        | 0.049            | Random              | 56.32% (47.65%-64.80%) |
| High troponin               | 30                         | 1485        | <0.01      | 95.50%        | 0.1324           | Random              | 76.34% (63.27%-87.27%) |
| BNP                         | 31                         | 1554        | <0.01      | 94.20%        | 0.0971           | Random              | 84.65% (74.95%-92.31%) |
| **Organ damage**            |                            |             |            |               |                  |                     |
| Liver function damage       | 16                         | 411         | <0.01      | 82.20%        | 0.0524           | Random              | 46.29% (32.78%-60.08%) |
| Renal function              | 26                         | 1463        | <0.01      | 84.90%        | 0.0296           | Random              | 27.67% (20.83%-35.08%) |
| **Laboratory inspection**   |                            |             |            |               |                  |                     |
| Leukocytosis                | 12                         | 401         | <0.01      | 73.30%        | 0.0394           | Random              | 55.30% (40.47%-69.66%) |
| Leukopenia                  | 10                         | 417         | <0.01      | 82.90%        | 0.0514           | Random              | 4.40% (0.14%-14.13%)  |
| Reduced lymphocytes         | 28                         | 1206        | <0.01      | 89.00%        | 0.0612           | Random              | 61.51% (50.73%-71.74%) |
| Elevated platelets          | 11                         | 421         | 0.05       | 44.90%        | 0.0093           | Fixed               | 10.35% (7.62%-13.43%) |
| Thrombocytopenia            | 20                         | 1368        | <0.01      | 87.70%        | 0.0326           | Random              | 26.42% (18.19%-35.58%) |
| CRP rise                    | 34                         | 1087        | <0.01      | 82.20%        | 0.0397           | Random              | 98.5% (95.04%-99.65%) |
| Elevated ferritin           | 28                         | 884         | <0.01      | 84.00%        | 0.0483           | Random              | 86.79% (79.32%-92.79%) |
| Elevated ESR               | 13                         | 475         | <0.01      | 75.90%        | 0.0253           | Random              | 82.44% (73.47%-98.89%) |
| Elevated PCT               | 17                         | 597         | <0.01      | 81.80%        | 0.0414           | Random              | 85.10% (75.65%-92.55%) |
## Table 1: Continued.

| Outcome indicators | Number of included studies | Sample size | Heterogeneity | Effect of model | Meta-analysis results |
|--------------------|----------------------------|-------------|---------------|----------------|----------------------|
|                    |                            |             | $P$ values    |                |                      |
| Elevated FIB       | 13                         | 414         | <0.01         | 86.80%         | 0.0658               | Random               | 87.01% (73.97%-95.98%) |
| hypoalbuminemia    | 14                         | 457         | <0.01         | 82.70%         | 0.0443               | Random               | 77.92% (66.00%-87.85%) |
| Elevated LDH       | 10                         | 478         | <0.01         | 98.00%         | 0.3994               | Random               | 80.59% (42.53%-99.73%) |
| Elevated IL-6      | 11                         | 527         | <0.01         | 91.90%         | 0.0814               | Random               | 24.69% (19.74%-29.99%) |
| Pulmonary ground glass change | 14 | 271    | <0.01         | 71.00%         | 0.0358               | Random               |                       |
| Severe disease and mortality | | | | | | | |
| PICU               | 48                         | 1949        | <0.01         | 83.40%         | 0.0346               | Random               | 72.79% (66.75%-78.44%) |
| Shock              | 42                         | 1804        | <0.01         | 85.30%         | 0.0384               | Random               | 55.68% (48.50%-62.74%) |
| Mortality          | 45                         | 2010        | <0.01         | 39.00%         | 0.0039               | Fixed                | 1.00% (0.61%-1.48%) |
| Treatment          |                            |             |               |                |                      |                      | |
| Invasive mechanical ventilation | 46 | 1565 | <0.01         | 85.45%         | 0.0451               | Random               | 22.68% (16.91%-29.02%) |
| ECMO               | 37                         | 1078        | <0.01         | 54.90%         | 0.0109               | Random               | 0.48% (0.03%-1.42%) |
| IVIG               | 47                         | 1959        | <0.01         | 86.00%         | 0.0413               | Random               | 82.15% (76.53%-87.14%) |
| Aspirin            | 20                         | 592         | <0.01         | 89.20%         | 0.0888               | Random               | 67.97% (53.77%-80.64%) |
| Glucocorticoid     | 40                         | 1869        | <0.01         | 86.90%         | 0.0401               | Random               | 59.32% (52.02%-66.43%) |
| Vasoactive agent   | 23                         | 955         | <0.01         | 83.90%         | 0.0493               | Random               | 45.79% (42.62%-48.97%) |
| Positive inotropic | 24                         | 939         | <0.01         | 87.40%         | 0.0493               | Random               | 58.99% (48.57%-69.02%) |
| IL-1 receptor antagonist | 16 | 516    | <0.01         | 76.50%         | 0.0293               | Random               | 3.61% (0.68%-8.73%) |
| IL-6 receptor antagonist | 18 | 518    | <0.01         | 91.30%         | 0.0106               | Random               | 10.9% (2.79%-23.42%) |
| Infliximab         | 14                         | 538         | <0.10         | 59.80%         | 0.013               | Random               | 6.68% (3.03%-11.62%) |
| Antibiotic         | 19                         | 528         | <0.11         | 81.90%         | 0.0562               | Random               | 90.96% (82.29%-96.92%) |

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; PCT = procalcitonin; FIB = fibrinogen; LDH = lactate dehydrogenase; IL-6 = interleukin-6; BNP = B type natriuretic peptide; ECMO = extracorporeal membrane oxygenation; IVIG = intravenous immunoglobulin.

## Table 2: Results of subgroup analysis.

| Outcome indicators | Number of included studies | Sample size | Heterogeneity | Effect of model | Meta-analysis results |
|--------------------|----------------------------|-------------|---------------|----------------|----------------------|
|                    |                            |             | $P$ values    |                |                      |
| Gastrointestinal symptoms |                      |             |               |                |                      |
| US                 | 21                         | 1208        | <0.01         | 72.80%         | 0.015               | Random               | 87.77% (85.86%-89.55%) |
| Europe             | 21                         | 753         | <0.01         | 79.90%         | 0.0325               | Random               | 76.53% (73.44%-79.48%) |
| Other countries    | 9                          | 165         | <0.01         | 61.60%         | 0.0231               | Random               | 70.54% (63.38%-77.23%) |
| $N < 50$           | 44                         | 757         | <0.03         | 70.10%         | 0.0345               | Random               | 84.11% (78.68%-88.87%) |
| $N \geq 50$        | 7                          | 1369        | <0.04         | 94.30%         | 0.0243               | Random               | 78.46% (67.80%-87.46%) |
| Respiratory symptoms |                      |             |               |                |                      |
| US                 | 17                         | 1128        | <0.01         | 88.60%         | 0.0393               | Random               | 47.68% (36.53%-58.94%) |
| Europe             | 12                         | 489         | <0.01         | 84.90%         | 0.0503               | Random               | 53.77% (38.615-68.59%) |
| Other countries    | 7                          | 136         | <0.01         | 84.60%         | 0.0354               | Random               | 67.01% (44.77%-85.83%) |
| $N < 50$           | 30                         | 500         | <0.01         | 81.30%         | 0.0667               | Random               | 54.98% (44.15%-65.57%) |
| $N \geq 50$        | 6                          | 1253        | <0.01         | 94.40%         | 0.0236               | Random               | 50.63% (37.88%-63.33%) |
| Lymphocytopenia    |                            |             |               |                |                      |
| US                 | 13                         | 1206        | <0.01         | 93.08%         | 0.0729               | Random               | 58.70% (41.92%-74.50%) |
| Europe             | 7                          | 77          | <0.01         | 70.90%         | 0.0629               | Random               | 84.01% (63.93%-96.84%) |
| Other countries    | 8                          | 134         | <0.01         | 40.70%         | 0.0112               | Fixed                | 48.96% (40.55%-57.40%) |
| $N < 50$           | 25                         | 351         | <0.01         | 77.40%         | 0.0627               | Random               | 62.05% (50.28%-73.14%) |
| $N \geq 50$        | 3                          | 855         | <0.01         | 98.40%         | 0.0718               | Random               | 58.4% (28.61%-85.23%) |
support. Similar to KD or toxic shock syndrome, most children had no obvious respiratory involvement. The incidence of respiratory symptoms in this study was only 53.02%.

In early stages of the pandemic, this disease was considered to be KD caused by COVID-19, because there are many symptoms of KD, such as rash, conjunctival congestion, chapped lips, and lymphadenitis. However, although there are some phenotypic similarities between MIS-C and KD, there are still many differences between the two diseases, such as the age of onset for KD being <5 years old, [68] and the median age in this study was >5 years old. In
KD, platelet count generally increased, while thrombocytopenia accounted for 26.42% of MIS-C cases. Gastrointestinal symptoms in KD and the degree of myocardial dysfunction are also rare, while myocarditis, coronary artery dilatation, cardiac systolic function affects, and gastrointestinal symptoms accounted for 35.97%, 17.83%, 56.32%, and 82.72% of cases, respectively, in MIS-C.

A similar systematic review was published in August this year. The gastrointestinal tract of MIS-C patients [69] was similar to that of this study, and the gastrointestinal symptoms were often abdominal pain. When exploratory abdominal surgery was performed under MIS-C, gastrointestinal investigations also showed mesenteric lymphadenitis and serous effusions (ascites) in severe cases, which implied an active inflammatory reaction had occurred in the digestive system [70]. However, it has been proven that angiotensin-converting enzyme 2 is highly expressed in the small intestine, especially in the proximal and distal intestinal epithelial cells, so the small intestine is more vulnerable to SARS-CoV-2 infection [71].

Laboratory examinations of MIS-C showed a significant increase in various inflammatory indicators, such as CRP, ESR, FIB, ferritin, and LDH. It is worth noting that 89.3% of patients had elevated IL-6, which was as sensitive as 98.5% of patients with elevated CRP. However, lymphocyte reduction was noted in 51.51% of patients, which was much higher than in the majority of cases of COVID-19 in children [72].

Generally, MIS-C is a more systemic disease, increasing the likelihood of organ damage or impairments of liver, kidney, and/or heart function (rather than damaging the respiratory tract or facilitating the pneumonia infection process), which can easily lead to hypotension and circulatory failure. The rate of admission to the PICU was 72.79%, and the rate of shock was 55.68%.

Nevertheless, prognosis is good if appropriate treatment measures are taken as early as possible, such as treatment in the intensive care unit, close monitoring, intravenous injection of immunoglobulin (82.15% utilization as used in the main treatment for KD) and corticosteroids (59.32% utilization), and use of biological agents and anticoagulants under the conditions recommended by appropriate specialists. Although the incidence of severe disease is high, 22.68% of the patients needed invasive mechanical ventilation and few patients (0.48%) required extracorporeal membrane oxygenation, only 1.00% of pediatric patients die, so the overall outcomes are good; however, the long-term cardiovascular outcomes have not been determined.

The limitations of this study are as follows: (1) as the syndrome was known by multiple names at the start of the pandemic, the standards of research inclusion vary from country to country, which may lead to inclusion biases; (2) we found there is great heterogeneity among the studies, and there is significant publishing bias among several subgroups; and (3) this study was analyzed during an ongoing pandemic, and many areas affected by COVID-19 have not yet published clinical datasets, which may lead to inaccurate analysis results.

5. Conclusions

The incidence of MIS-C, which presents as multiple organ injuries and systemic inflammatory reactions, is low. MIS-C has a high rate of severity and patients are prone to symptoms of shock; however, if it is identified and treated in time, the mortality rate can remain low.

Abbreviations

CRP: C-reactive protein
ESR: Erythrocyte sedimentation rate
PCT: Procalcitonin
FIB: Fibrinogen
LDH: Lactate dehydrogenase
IL-6: Interleukin-6
BNP: B-type natriuretic peptide
ECMO: Extracorporeal membrane oxygenation
IVIG: Intravenous immunoglobulin.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Concept and design were proposed by Ji-Gan Wang and Zhi-Juan Zhong. Acquisition, analysis, and interpretation of data were carried out by Ji-Gan Wang, Yu-Heng Su, and Yu-Li Huang. Drafting of the manuscript was performed by Ji-Gan Wang, Jun Fu, and Meng Li. Statistical analysis was conducted by Ji-Gan Wang and You-Min Ping. Administrative, technical, or material support was provided by Zi-Ji
Xu and Hao Li. Supervision was done by Yan-Hao Chen and Yu-Li Huang. Ji-Gan Wang and Zhi-Juan Zhong contributed equally to this work.

Acknowledgments
This study was funded by Self-Funded Scientific Research Project of Guangxi Zhuang Autonomous Region Health Commission (nos. Z20210123 and Z20180083).

 Supplementary Materials

Supplementary Table 2. Literature quality score table. Supplementary Table 1. Characteristics of studies included in the meta-analysis. (Supplementary Materials)

References

[1] D. Cucinotta and M. Vanelli, “WHO declares COVID-19 a pandemic,” Acta Bio-Medica: Atenei Parmensis, vol. 91, pp. 157–160, 2020.
[2] M.-Y. Zhou, X.-L. Xie, Y.-G. Peng et al., “From SARS to COVID-19: what we have learned about children infected with COVID-19,” International Journal of Infectious Diseases, vol. 96, pp. 710–714, 2020.
[3] K.-L. Shen, Y.-H. Yang, et al., “Updated consensus statement (condensed version of the second edition),” World Journal of Pediatrics, vol. 16, no. 3, pp. 232–239, 2020.
[4] S. Riphagen, X. Gomez, C. Gonzalez-Martinez, N. Wilkinson, and P. Theoharis, “Hyperinflammatory shock in children during COVID-19 pandemic,” The Lancet, vol. 395, no. 10237, pp. 1607–1608, 2020.
[5] M. Dolhnikoff, J. Ferreira Ferranti, R. A. de Almeida Monteiro et al., “SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome,” The Lancet Child & Adolescent Health, vol. 4, no. 10, pp. 790–794, 2020.
[6] L. A. Henderson, S. W Canna, K. G Friedman et al., “American College of Rheumatology clinical guidance for pediatric patients with multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 and hyperinflammation in COVID-19. Version 2,” Arthritis & Rheumatology (Hoboken, N.J.), vol. 73, 2020.
[7] D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement,” PLoS Medicine, vol. 6, no. 7, Article ID e1000097, 2009.
[8] H. Tam, T. El Tal, E. Go, and R. S. M. Yeung, “Pediatric inflammatory multisystem syndrome temporally associated with COVID-19: a spectrum of diseases with many names,” Canadian Medical Association Journal, vol. 192, no. 38, pp. E1093–e1096, 2020.
[9] C. Abraham, M. P. Kelly, R. West, and S. Michie, “The UK National Institute for Health and Clinical Excellence public health guidance on behaviour change: a brief introduction,” Psychology, Health & Medicine, vol. 14, no. 1, pp. 1–8, 2009.
[10] R. DerSimonian and R. Kacker, “Random-effects model for meta-analysis of clinical trials: an update,” Contemporary Clinical Trials, vol. 28, no. 2, pp. 105–114, 2007.
[11] E. Whittaker, A. Bamford, J. Kenny et al., “Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2,” Jama, vol. 324, no. 3, pp. 259–269, 2020.
[12] J. Toubiana, C. Poirault, A. Corsia et al., “Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study,” Bmj, vol. 369, 2020.
[13] M. Pouletty, C. Borocco, N. Ouldali et al., “Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort,” Annals of the Rheumatic Diseases, vol. 79, no. 8, pp. 999–1006, 2020.
[14] E. M. Dufort, E. H. Koumans, E. J. Chow et al., “Multisystem inflammatory syndrome in children in New York state,” New England Journal of Medicine, vol. 383, no. 4, pp. 347–358, 2020.
[15] E. Blumfeld and T. L. Levin, “COVID-19 in pediatric patients: a case series from the Bronx, NY,” Pediatric Radiology, vol. 50, no. 10, pp. 1369–1374, 2020.
[16] T. Rogo, K. Mathur, and M. Puruwani, “Systemic inflammation with cardiac involvement in pediatric patients with evidence of COVID-19 in a community hospital in the Bronx, New York,” Journal of the Pediatric Infectious Diseases Society, vol. 9, no. 4, pp. 502-503, 2020.
[17] M. Grimaud, “Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children,” Annals of Intensive Care, vol. 10, 69 pages, 2020.
[18] C. Diorio, S. E Henrickson, L. A Vella et al., “Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2,” The Journal of Clinical Investigation, vol. 130, pp. 5967–5975, 2020.
[19] M. Sadiq, O. A. Aziz, U. Kazmi et al., “Multisystem inflammatory syndrome associated with COVID-19 in children in Pakistan,” The Lancet Child & Adolescent Health, vol. 4, no. 10, pp. e36–e37, 2020.
[20] S. M. Heidemann, B. Tiflford, C. Bauerfeld et al., “Three cases of pediatric multisystem inflammatory syndrome associated with COVID-19 due to SARS-CoV-2,” American Journal of Case Reports, vol. 21, Article ID e295779, 2020.
[21] S. Jain, “Multisystem inflammatory syndrome in children with COVID-19 in Mumbai, India,” Indian Pediatrics, vol. 57, pp. 1015–1019, 2020.
[22] A. Cantor, J. Miller, P. Zachariah, B. D’Silva, K. Margolis, and M. Martinez, “Acute hepatitis is a prominent presentation of the multisystem inflammatory syndrome in children: a single-center report,” Hepatology, vol. 72, no. 5, pp. 1522–1527, 2020.
[23] K. Dhanalakshmi, “Epidemiological and clinical profile of pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in Indian children,” Indian Pediatrics, vol. 57, pp. 1010–1014, 2020.
[24] S. Mamishi, Z. Movahedi, M. Mohammadi et al., “Multisystem inflammatory syndrome associated with SARS-CoV-2 infection in 45 children: a first report from Iran,” Epidemiology and Infection, vol. 148, e196 pages, 2020.
[25] K. F. Ng, T. Kothari, S. Bandi et al., “COVID-19 multisystem inflammatory syndrome in three teenagers with confirmed SARS-CoV-2 infection,” Journal of Medical Virology, vol. 92, no. 11, pp. 2880–2886, 2020.
[26] K. Chiotis, H. Bassiri, E. M. Behrens et al., “Multisystem inflammatory syndrome in children during the coronavirus 2019 pandemic: a case series,” Journal of the Pediatric Infectious Diseases Society, vol. 9, no. 3, pp. 393–398, 2020.
[27] E. Blondiaux, P. Pariset, A. Redheuil et al., “Cardiac MRI in children with multisystem inflammatory syndrome associated...
characteristics and an institutional protocol for evaluation, management, and follow-up,” *Pediatric Critical Care Medicine*, vol. 22, no. 3, pp. e178–e191, 2020.

[57] S. Felsenstein, E. Willis, H. Lythgoe et al., “Presentation, treatment response and short-term outcomes in paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS),” *Journal of Clinical Medicine*, vol. 9, no. 10, 3293 pages, 2020.

[58] C. Moraleda, “Multi-inflammatory syndrome in children related to SARS-CoV-2 in Spain,” *Clinical Infectious Diseases*, vol. 72, 2020.

[59] I. Valverde, Y. Singh, J. Sanchez-de-Toledo et al., “Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe,” *Circulation*, vol. 143, no. 1, pp. 21–32, 2021.

[60] S. Grazioli, F. Tavaglione, G. Torriani et al., “Immunological assessment of pediatric multisystem inflammatory syndrome related to coronavirus disease 2019,” *Journal of the Pediatric Infectious Diseases Society*, vol. 142, 2020.

[61] C. N. Gruber, R. S. Patel, R. Trachtman et al., “Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C),” *Cell*, vol. 183, no. 4, pp. 982–995, 2020.

[62] A. Dionne, D. Y. Mah, M. B. F. Son et al., “Atrioventricular block in children with multisystem inflammatory syndrome,” *Pediatrics*, vol. 146, no. 5, 2020.

[63] K. N. Clouser, J. Gadhavi, S. M. Bhavsar et al., “Short-term outcomes after multisystem inflammatory syndrome in children treatment,” *Journal of the Pediatric Infectious Diseases Society*, vol. 10, no. 1, pp. 52–56, 2020.

[64] L. M. Prieto, B. Toral, A. Llorente, and D. Blázquez-Gamero, “Cardiovascular magnetic resonance imaging in children with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 and heart dysfunction,” *Clinical Microbiology and Infection*, vol. 27, no. 4, pp. 648–650, 2021.

[65] N. U. Falah, S. Hashmi, Z. Ahmed et al., “Kawasaki disease-like features in 10 pediatric COVID-19 cases: a retrospective study,” *Cureus*, vol. 12, 2020.

[66] M. S. Kelly, C. W. Valle, N. D. Fernandes, B. M. Cummings, M. Lahoud-Rahme, and J. S. Chiu, “Multisystem inflammatory syndrome in children: cardiac biomarker profiles and echocardiographic findings in the acute and recovery phases,” *Journal of the American Society of Echocardiography*, vol. 33, no. 10, pp. 1288–1290, 2020.

[67] H. K. Kanthimathinathan and B. R. Scholefield, “Pediatric inflammatory multisystem syndrome: time to collaborate,” *Journal of the Pediatric Infectious Diseases Society*, vol. 10, no. 3, pp. 227–229, 2020.

[68] B. W. McCrindle, A. H. Rowley, J. W. Newburger et al., “Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association,” *Circulation*, vol. 135, no. 17, pp. e927–e999, 2017.

[69] J. Y. Abrams, S. E. Godfred-Cato, M. E. Oster et al., “Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: a systematic review,” *The Journal of Pediatrics*, vol. 226, pp. 45–54, 2020.

[70] T.-H. Chen, W.-T. Kao, and Y.-H. Tseng, “Gastrointestinal involvements in children with COVID-related multisystem inflammatory syndrome,” *Gastroenterology*, vol. 160, no. 5, pp. 1887-1888, 2021.

[71] W. Liang, Z. Feng, S. Rao et al., “Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus,” *Gut*, vol. 69, no. 6, pp. 1141–1143, 2020.

[72] M. A. Yoldas and H. Yoldas, “Pediatric COVID-19 disease: a review of the recent literature,” *Pediatric Annals*, vol. 49, no. 7, pp. e319–e325, 2020.